About us: who we are
CELYSTRA Pharma is a Quebec-based biopharmaceutical company specializing in the introduction of innovative treatments to Canada.
Founded by three pharmaceutical industry veterans, the company identifies and acquires innovative therapies developed internationally and brings them to underserved patient populations in Canada.
Based in Montreal and active within Quebec’s life sciences ecosystem, CELYSTRA works with global partners to help bring new treatments to patients who need them.
Health Canada-approved
In rare and specialty diseases, unmet need isn’t just a gap in treatment — it’s families waiting, patients hoping, and time we cannot afford to lose. We built this company to ensure that innovative science reaches the people whose lives depend on it.
Paul Lévesque
President and Chief Executive Officer
Our approach
A Focused Path from Innovation to Access
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur auctor arcu sit amet mauris pellentesque vulputate.
Innovation
Identifying and acquiring innovative therapies developed internationally.
Partnerships
Working with global partners to help bring new treatments to patients.
Access
Facilitating access in Canada to medicines that address unmet medical needs.
Our focus
Bringing innovative treatments to Canadian patients — from regulatory approval to commercial success
CELYSTRA begins its activities with a treatment recently approved by Health Canada for familial chylomicronemia syndrome (FCS), a rare genetic disease characterized by severely elevated triglyceride levels in the blood.
Although the disease affects only an estimated 2 to 10 people per million worldwide, its prevalence is significantly higher in certain founder populations, including French Canadians, particularly in eastern Quebec.
Partnership & Collaborations
Your Science. Our Expertise. Faster to Patients.
You’ve done the hard work. We bring the commercial engine, the regulatory know-how, and the rare disease networks to take it across the finish line. If you’re ready to move from promising to proven — let’s talk.